News

Add Ajanta Pharma Ltd For Target Rs. 2,750 By Yes Securities Result Synopsis Ajanta management reiterated robust growth expectation across branded generic markets of Asia and Africa though it appears Q1 performance may not be completed replicated across quarters. Domestic business should see the impact of Met XL NLEM inclusion recede as volumes rebound (Q1 cardiac growth of 14% vs 5% on 12mth MAT basis in June). US business has been caught in a range due to lack of approvals which might could be change in H2 and next fiscal as company alluded to spa...
Add Ajanta Pharma Ltd For Target Rs. 2,750 By Yes Securities
Add Ajanta Pharma Ltd For Target Rs. 2,750 By Yes Securities
Source: Yes Securities Ltd.
2024-08-20 05:26:04 pm
Buy Ajanta Pharma Ltd For Target Rs. 2,758 By Choice Broking Ltd Ajanta Pharma Ltd. reported earnings were above our estimates. Revenue at INR 11,449mn (+12.1% YoY and +8.6% QoQ) came on the back of robust performance in India and African Branded business. EBITDA margin grew by 228bps YoY and 245bps QoQ at 28.9% attributed to the combined benefits of reduction in API prices, decline in logistic costs, and stabilization in US Price erosion. The management expects consolidated low teens top-line growth in FY25, driven by branded generic and India business. ...
Buy Ajanta Pharma Ltd For Target Rs. 2,758 By Choice Broking Ltd
Buy Ajanta Pharma Ltd For Target Rs. 2,758 By Choice Broking Ltd
Source: Choice Broking Ltd
2024-08-08 02:38:22 pm
Ajanta Pharma moves up on reporting 18% rise in Q1 consolidated net profit Ajanta Pharma is currently trading at Rs. 2620.00, up by 97.25 points or 3.85% from its previous closing of Rs. 2522.75 on the BSE. The scrip opened at Rs. 2544.75 and has touched a high and low of Rs. 2556.15 and Rs. 2507.00 respectively. So far 2910 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2576.25 on 30-Jul-2024 and a 52 week low of Rs. 1624.80 on 31-Jul-2023. Last one week high and low of the scrip sto...
Ajanta Pharma moves up on reporting 18% rise in Q1 consolidated net profit
Ajanta Pharma moves up on reporting 18% rise in Q1 consolidated net profit
Source: Accord Fintech
2024-07-31 11:07:15 am
Add Ajanta Pharma Ltd For Target Rs.2,550 by Yes Securities Export growth, margin uptick remains key drivers We capture and expand the key highlights of our recent conversation with Ajanta Pharma in this update. Domestic growth is being driven by dermatology as was the case in FY24 while Met XL continues to weigh on cardiac sales. We reckon the top cardiac brand would deliver only 2-3% volume growth as price hike is limited in current year. About 25% of new launches in domestic business continue to be of the first to market kind, as in the past whi...
Add Ajanta Pharma Ltd For Target Rs.2,550 by Yes Securities
Add Ajanta Pharma Ltd For Target Rs.2,550 by Yes Securities
Source: Yes Securities Ltd.
2024-07-20 09:45:41 am
Select healthcare stocks witness gains on the BSE Select healthcare stocks witnessed gains on the BSE during the afternoon deals. Ajanta Pharma, Abbott India and Cipla were among gainers in the healthcare index. Abbott India is currently trading at Rs. 27356.90, up by 351.90 points or 1.30% from its previous closing of Rs. 27005.00 on the BSE. Ajanta Pharma is currently trading at Rs. 2093.00, up by 5.40 points or 0.26% from its previous closing of Rs. 2087.60 on the BSE. Cipla is currently trading at Rs. 1467.95, up by 2.65 points ...
Select healthcare stocks witness gains on the BSE
Select healthcare stocks witness gains on the BSE
Source: Accord Fintech
2024-03-13 03:51:54 pm
Buy Ajanta Pharma Ltd For Target Rs.2,020 - Yes Securities Earnings certainty to sustain multiples Result Synopsis Ajanta management alluded to higher other expenses and marginal rise in R&D spending in H2 though margin performance YTD results in 1% raise in margin guidance. Growth outlook remains unchanged for domestic business even as cardiac growth recovers post NLEM impact on MetXL. Branded exports might be tad weaker as Asia business remained under pressure; albeit company expects to H2 recovery with low teens growth. US surprised on t...
Buy Ajanta Pharma Ltd For Target Rs.2,020 - Yes Securities
Buy Ajanta Pharma Ltd For Target Rs.2,020 - Yes Securities
Source: Yes Securities Ltd
2023-11-15 11:05:31 am
Buy Ajanta Pharmaceuticals Ltd For Target Rs.2,030 - Motilal Oswal Financial Services India/US drive earnings Marketing spend to increase in the near term * Ajanta Pharma (AJP) delivered in-line 2QFY24 earnings. The operating profit margin has been on a sharp revival trend with 630bp/70bp improvement on YoY/QoQ basis. Healthy performance in domestic formulation (DF), US, and branded Africa markets, coupled with favourable cost factors, is driving better profitability for AJP. * We maintain our earnings estimate for FY24/FY25. We value AJP at 25x 12M forward earnings t...
Buy Ajanta Pharmaceuticals Ltd For Target Rs.2,030 - Motilal Oswal Financial Services
Buy Ajanta Pharmaceuticals Ltd For Target Rs.2,030 - Motilal Oswal Financial Services
Source: Motilal Oswal Financial Services Ltd
2023-11-07 11:48:50 am